Kevin L. Cornwell, Chairman and CEO of Utah Medical Products Inc, filed a Form 4 on October 29, 2026, reporting the purchase of 1,000 shares of common stock on that same date.

Key Highlights

  • Reporting person: Kevin L. Cornwell, serving as Chairman and CEO, and also listed as a Director.
  • Transaction: Purchase (code P) of 1,000 shares of common stock on October 29, 2026.
  • Price paid: $66.75 per share, according to the filing.
  • Post-transaction indirect ownership: 189,472 shares beneficially owned indirectly following the reported transaction.
  • Ownership structure: The 189,472 shares are held across three vehicles: 6,000 shares in Cornwell's own IRA, 128,478 shares in the Cornwell Bypass Trust, and 54,994 shares in the Cornwell Survivor's Trust.
  • Filing basis: Filed by one reporting person; no amendment date indicated.

Cornwell's October 2026 Open-Market Purchase of Utah Medical Products Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Kevin L. Cornwell, who holds the roles of Chairman, CEO, and Director at Utah Medical Products Inc (NASDAQ:UTMD), reported an open-market purchase of 1,000 shares of the company's common stock. The transaction was dated October 29, 2026, with a stated price of $66.75 per share. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan.

The filing reports that all 189,472 shares beneficially owned following the transaction are held indirectly. As detailed in the explanation of responses, these consist of 6,000 shares held in Cornwell's own IRA, 128,478 shares held by the Cornwell Bypass Trust, and 54,994 shares held by the Cornwell Survivor's Trust. No directly owned shares are reported in Table I, and no derivative securities are reported in Table II.

The Form 4 was signed by Kevin L. Cornwell and dated October 29, 2026. The filing was submitted by one reporting person. No amendment to a prior filing was indicated, and no deemed execution date was listed for the transaction.

What Was Disclosed

The filing discloses a single open-market purchase of 1,000 shares of Utah Medical Products Inc common stock by Chairman and CEO Kevin L. Cornwell at $66.75 per share on October 29, 2026, resulting in 189,472 indirectly held shares beneficially owned.